The effective targeting of RAS-mutant acute myeloid leukemia (AML) still remains a challenge; RAS mutations are tied to relapse to targeted therapy, such as resistance to FLT3 inhibitors due to the ...

Approximately 30% of individuals with myeloid malignancy diseases have a ... A study published Oct. 2 in Nature is the first ...

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...

the disproportionate activation of the triggering receptor expressed on myeloid cells 1 (TREM-1) pathway. TREM-1 is an immune receptor expressed by myeloid and endothelial cells. Inotrem has ...